NCT03492125 2025-04-10
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
NCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT03145480 2023-06-01
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Northwell Health
Phase 2 Terminated
NCT02292225 2023-02-27
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
Phase 1 Terminated
NCT02225275 2022-09-28
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03759184 2022-03-22
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01644253 2021-05-20
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics
Phase 1 Terminated
NCT02336048 2021-04-08
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Hoffmann-La Roche
Phase 1 Terminated
NCT01980875 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated